Zusammenfassung
Das Rabbit-Syndrom (RS) ist eine seltene extrapyramidale Nebenwirkung unter neuroleptischer Medikation. Es ist durch unwillkürliche, rhythmische Dyskinesien des Mundes und der Lippen unter Aussparung der Zunge charakterisiert, und wird hauptsächlich unter typischen Neuroleptika beobachtet. Auch unter den atypischen Neuroleptika Risperidon und Aripiprazol ist dieses Syndrom wiederholt beobachtet worden. Wir berichten von einer 74-jährigen Patientin mit einer bipolaren affektiven Störung, welche unter der Einnahme von 20 mg/d Olanzapin ein RS entwickelte. Dies ist unserem Wissen nach der erste Fallbericht eines RS unter Olanzapin.
Abstract
Rabbit syndrome (RS) is a rare extrapyramidal side effect of antipsychotic treatment. It is characterized by involuntary, rhythmic dyskinesias of mouth and lips excluding the tongue, and is most common under typical neuroleptics. There are also several reports of the syndrome in patients with the atypical antipsychotics risperidone and aripiprazole. We report a 74 year-old patient suffering from a bipolar affective disorder, who developed a rabbit syndrome following the intake of 20 mg/d olanzapine. To our knowledge this is the first case report of a RS due to olanzapine.
Literatur
-
1
Villneuve A.
The rabbit syndrome: a peculiar extrapyramidal reaction.
Can Psychiatry Assoc J.
1972;
17
69-72
-
2
Yassa R, Lal S.
Prevalence of the rabbit syndrome.
Am J Psychiatry.
1986;
143
656-657
-
3
Chiu H F, Lam L C, Chung D W, Wing Y K, Schum P P.
Prevalence of the rabbit syndrome in Hong Kong.
J Nerv Ment Disord.
1993;
181
264-265
-
4
Hoy J S, Alexander B D.
Rabbit Syndrome secondary to Risperidone.
Pharmacotherapy.
2002;
22
513-515
-
5
Schwartz M, Beny A, Sharf B.
Risperidone-induced rabbit syndrome.
Br J Psychiatry.
1998;
173
267-268
-
6
Levin T, Heresco-Levy U.
Risperidone-induced rabbit syndrome: an unusual movement disorder caused by an atypical antipsychotic.
Eur Neuropsychopharm.
1999;
9
137-139
-
7
Mendhekar D N.
Aripiprazole-induced rabbit syndrome.
Austr New Zea J Psychiatry.
2004;
38
561
-
8
Durst R, Katz G, Zislin J, Raskin S, Kalman I.
Rabbit syndrome treated with olanzapine.
Br J Psychiatry.
2000;
176
193
-
9
Fornazzari L, Ichise M, Remington G, Smith I.
Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.
J Psychiatry Neurosci.
1991;
16
227-229
-
10
Schwartz M, Hocherman S.
Antipschotic-induced rabbit syndrome: epidemiology, management and pathophysiology.
CNS Drugs.
2004;
18
213-220
-
11
Nishimura K, Tuska M, Horikawa N.
Withdrawal-emergent rabbit syndrome during dose reduction of risperodone.
Eur Neuropsychopharmacol.
2001;
11
323-324
-
12
Kamijo Y, Soma K, Fukuda M, Asari Y, Ohwada T.
Rabbit syndrome following phenol ingestion.
J Toxicol Clin Toxicol.
1999;
37
509-511
-
13
Villeneuve A, Lajeunesse C.
Clinical aspects of tardive dyskinesias induced by neuoleptics.
Encephale.
1988;
14
S209-214
-
14
Goetz C G, Blasucci L M, Leurgans S, Pappert E J.
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patient.
Neurology.
2000;
55
789-794
-
15
Marsh L, Lyketsos C, Reich S C.
Olanzapine for the treatment of psychosis with parkinson's disease and dementia.
Psychosomatics.
2001;
42
477-481
-
16
Molho E, Factor S.
Worsening of motor features of Parkinson's disease with olanzapine.
Mov Disord.
1998;
13
256
-
17
Jemenez-Jemenez F, Tallo-Baranco O, Pareva O.
Olanzapine can worsen parkinsonism.
Neurology.
1998;
50
1183-1184
-
18
Ciudad A, Montes J M, Olivares J M, Gomez J C.
Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.
Eur Psychiatry.
2004;
19
358-65
-
19
Kopf A, Köster J, Schulz A, Krömker H, Becker T.
Life threatening neuroleptic malignant syndrome due to olanzapine.
Psychiat Prax.
2003;
30
279-282
-
20
Mancini F, Tassorelli C, Martignoni E, Moglia A, Nappi G, Cristina S, Pacchetti C.
Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease.
Clin Neuropharmacol.
2004;
27
33-37
-
21
Juncos J L, Roberts V J, Evatt M L, Jewart R D, Wood C D, Potter L S, Yeung P P.
Quetiapine improves psychotic symptoms and cognistion in Parkinson's disease.
Mov Disord.
2004;
19
29-35
-
22
Fernandez H H, Trieschmann M E, Burke M A, Jacques C, Friedman J H.
Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
Mov Disord.
2003;
18
510-514
-
23
Pollak P.
Psychic disorders.
Rev Neurol.
2002;
158
S125-131
-
24
Reddy S, Factor S A, Molho E S, Feustel P J.
The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
Mov Disord.
2002;
17
676-681
-
25
Targum S D, Abbott J L.
Efficacy of quetiapine in Parkinson's patients with psychosis.
J Clin Psychopharmacol.
2000;
20
54-60
-
26
Sethi S, Bhargava S C.
Clozapine-induced rabbit syndrome.
J Clin Psychiatry.
2003;
64
219
Dr. med. Michael Sabolek
Abt. Psychiatrie II der Universität Ulm · Bezirkskrankenhaus Günzburg
Ludwig-Heilmeyer-Straße 2
89312 Günzburg
Email: michael.sabolek@medizin.uni-ulm.de
